Binoy Bhansali was previously at Sandbox Industries, which manages $1.2bn across four funds for health insurer Blue Cross Blue Shield.

IBM Ventures participated in a $20m round for the neurological disease diagnostics technology spinout of Tel Aviv University.

Q&A with Kurt Sheline, principal, Echo Health Ventures

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Miyako Capital has contributed to a series A round for the cancer vaccine developer, which expanded to Japan last year.

The money will fund the progress of the University of London-linked precision medicine developer's lead drug candidate into the clinic.

Konishiyasu and Sojitz contributed to a series A round for the cancer vaccine developer, which expanded to their home of Japan last year.

SoftBank Vision Fund 2, Itochu and an unnamed insurer took part in a series C round that hiked the gene and cell therapy developer's total funding to $845m.

IBM Ventures participated in a $20m round for the neurological disease diagnostics technology developer, a spinout from Tel Aviv University.

The ophthalmic treatment developer has now raised almost $36m in total, with CR-CP Life Science Fund having led a $25m round.